AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.
The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.
These three companies have the potential to double their share price from current levels. Here's why.
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
AbbVie Inc has agreed to pay $21 billion to acquire Pharmacyclics, Inc.
Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.
Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.
Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.
The NFL is unquestionably one of the most successful American businesses of all-time. Surprisingly, though, the NFL's 2013 revenues were no match for this single legal drug.
AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?